ABSTRACT
AIMS: There is a lack of biomarkers validated for assessing clinical deterioration in patients with COVID-19 on presentation to secondary or tertiary care. This evaluation looked at the potential clinical application of C reactive protein (CRP), procalcitonin, mid-regional proadrenomedullin (MR-proADM) and white cell count to support prediction of clinical outcomes. METHODS: 135 patients presenting to Hampshire Hospitals NHS Foundation Trust between April and June 2020 confirmed to have COVID-19 via reverse-transcription-qPCR were included. Biomarkers from within 24 hours of presentation were used to predict disease progression by Cox regression and area under the receiver operating characteristic curves. The endpoints assessed were 30-day all-cause mortality, intubation and ventilation, critical care admission and non-invasive ventilation (NIV) use. RESULTS: Elevated MR-proADM was shown to have the greatest ability to predict 30-day mortality adjusting for age, cardiovascular disease, renal disease and neurological disease. A significant association was also noted between raised MR-proADM and CRP concentrations and the requirement for critical care admission and NIV. CONCLUSIONS: The measurement of MR-proADM and CRP in patients with confirmed COVID-19 infection on admission shows significant potential to support clinicians in identifying those at increased risk of disease progression and need for higher level care, subsequently enabling prompt escalation in clinical interventions.
ABSTRACT
Feline Infectious Peritonitis (FIP) is highly mortality disease in cats. The reliable and fast diagnosis is crucial to the best prognosis. The aim of this study to evaluate the hemogram profile in cats infected with effusive FIP. Twenty cats had been diagnosed effusive FIP at Animal Clinic Department of Internal Medicine, Faculty Veterinary Medicine, Universitas Gadjah Mada were used in the study. The diagnosis were based on clinical examination, ultrasound, x-ray, rivalta test, and rapid test. The hemogram profile were analyzed include routine hematology and serum biochemistry. Hemogram profile in effusive FIP showed the decreased hematocrit, hyperproteinemia, and leukocytosis with an average 22.9+or-7.4%;9.0+or-2.2 g/dL;22425+or-4116 cells/mm3 respectively. Erythrocyte, hemoglobin and fibrinogen levels were still in the normal range. The results of differential leukocytes revealed that 90% cats had neutrophilia and 75% lymphopenia with an average 20066+or-3337 cells/mm3 and 1861+or-1818 cells/mm3 respectively. The blood chemistry profile showed 60% of cats experienced increase in SGPT and SGOT with an average 138.4+or-72.3 IU/L and 101+or-60.5 IU/L respectively. Hyperglobulinemia was found in 90% samples with an average 6.7+or-0.8 g/dL. All cats have a low albumin:globulin ratio with an average 0.3+or-0.1. The hemogram profile of effusive FIP were: leukocytosis, neutrophilia, lymphopenia, hyperglobulinemia, and decreased albumin-globulin ratio..
ABSTRACT
P700 A novel platform for engineered AAV-based vaccines S Babutzka SP 1 sp L Zobel SP 1 sp J Bogedein SP 1 sp M Diedrichs-Möhring SP 1 sp M Gehrke SP 1 sp G Wildner SP 1 sp H Ammer SP 2 sp S Michalakis SP 1 sp I 1: Department of Ophthalmology, University Hospital, LMU Munich, 80336 Munich, Germany 2: Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, Munich, Germany i The still ongoing pandemic has highlighted the unmet need for more innovative and rapidly adaptable vaccine platforms. P702 Circumventing anti-vector immunity towards adenoviral vectored vaccines C M Bliss SP 1 sp J A Davies SP 1 sp M Marusková SP 1 sp L M Badder SP 1 sp M A Oliver SP 2 sp L Stack SP 1 sp A T Baker SP 1 sp A L Parker SP 1 sp I 1: Cardiff University 2: InBio i Replication deficient (RD) adenoviruses (Ad) are the most widely administered viral vectors, with licensed SARS-CoV-2 vaccines using vectors derived from human Ad type 5 (Ad5) and 26 (Ad26), and chimpanzee Ad " I ChAdOx1 i ". P704 Characterization of adenovirus interactions with PF4 using a novel ELISA-qPCR technology E Sallard SP 1 sp F Kreppel SP 1 sp A Ehrhardt SP 1 sp I 1: Witten/Herdecke University i The COVID vaccines Janssen and AstraZeneca, based respectively on adenovirus (AdV) serotypes AdV26 and ChAdOx1, have been associated with rare cases of vaccine-induced thrombotic thrombocytopenia (VITT). This next-generation vaccine platform based on AAV capsids with large insertions of immunogenic sequences enables strong and specific immune responses without the need for genomically encoded immunogens, thus reducing the risk of potentially pathogenic intracellular processes associated with viral vector genomes and prolonged transgene expression. [Extracted from the article]
ABSTRACT
Objective: To analyse whether prealbumin could be a new biomarker for predicting mortality in severe COVID-19 patients. Study Design: An observation study. Place and Duration of Study: Intensive care units (ICU) of Sakarya University Training and Research Hospital, Sakarya, Turkey, from October 2020 to December 2020. Methodology: The data of 149 patients, who were admitted to the ICU were collected and analysed retrospectively. Routine blood samples were collected from all patients at the time of admission to the ICU;and 102 patients with the mortal course and 47 patients with the non-mortal course were included in the study. The data obtained from these patients were analyzed in the biostatistics programme.
ABSTRACT
TBI alone and in combination with polytrauma and lung injury caused up to 83 percent of nonsurvivable combat-related deaths. There is no accurate diagnosis method or viable therapeutic intervention for these casualties primarily due to the severity of injury, which can be unrecognized early on. Our proposal will address these unmet needs via utilization of a model of TBI with targeted descriptors of injury severity derived from bedside cell free DNA (cfDNA) testing, and then via addition of polytrauma and lung injury with subsequent testing of therapeutic intervention via extracorporeal life support (ECLS).
ABSTRACT
The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population underscores the need for broadly active countermeasures. We employed a directed evolution approach to engineer three SARS-CoV-2 antibodies for enhanced neutralization breadth and potency. One of the affinity-matured variants, ADG-2, displays strong binding activity to a large panel of sarbecovirus receptor binding domains (RBDs) and neutralizes representative epidemic sarbecoviruses with high potency. Structural and biochemical studies demonstrate that ADG-2 employs a distinct angle of approach to recognize a highly conserved epitope overlapping the receptor binding site. In immunocompetent mouse models of SARS and COVID-19, prophylactic administration of ADG-2 provided complete protection against respiratory burden, viral replication in the lungs, and lung pathology. Altogether, ADG-2 represents a promising broad-spectrum therapeutic candidate against clade 1 sarbecoviruses.
ABSTRACT
Medical Problem to Be Addressed: Fractures to the limbs are one of the most common injuries that service men and women will experience both during training and in combat. X-rays and verbal questions about how the injured bone feels (if there is pain and if the person can use the injured limb) are the current approaches used to follow the progress of bone healing. Failed healing as diagnosed by X-ray and pain is made many months after the biology of healing has actually failed. This means that if there was a tool to follow the biology of healing, diagnosis of failed healing could be made at a significantly earlier timepoint, leading to earlier intervention for failed healing and shortening the periods that patients are subjected to pain and disability. Rationale for Project: A few studies to date have shown that specific proteins associated with the various biological stages of fracture healing, are released from the fractured bone into the serum (blood) and assaying for their presence can be used to follow bone healing. This leads us to believe that we can successfully develop a serum protein based biological diagnostic to both follow the progression of fracture healing and identify failed healing at much earlier times than X-Rays.
ABSTRACT
Prompt identification of the clinical status and severity of COVID-19 can be a challenge in the emergency department (ED), as the clinical severity of the disease is variable, real-time reverse-transcription PCR (RT-PCR) results may not be immediately available, and imaging findings appear approximately 10 days after the onset of symptoms. There is currently no set of simple, readily available and fast battery of tests that can be used in the ED as prognostic factors. The purpose was to study laboratory test results in patients with COVID-19 at hospital emergency admission and to evaluate the results in non-survivors and their potential prognostic value. A profile of laboratory markers was agreed with the ED providers based on the International Federation of Clinical Chemistry and Laboratory Medicine recommendation of its usefulness, which was made in 218 patients with COVID-19. Non-survivors were significantly older, and the percentage of patients with pathological values of creatinine, albumin, lactate dehydrogenase (LDH), C reactive protein, prothrombin time, D-dimer, and arterial blood gas, PaO2/FIO2 and satO2/FIO2 indices were significantly higher among the patients with COVID-19 who died than those who survived. Patients who died also presented higher neutrophil counts. Among all studied tests, albumin and LDH were independent prognostic factors for death. The results of the study show pathology in nine laboratory markers in patients with COVID-19 admitted in the ED, valuable findings to take into consideration for its prompt identification when there is no immediate availability of RT-PCR results.